HOME >> MEDICINE >> NEWS
Triple-drug therapy promising against African HIV subtype

Triple-drug antiretroviral regimens that are widely used in the United States and Europe against one HIV-1 subtype appear to be effective in South African patients infected with a different HIV-1 subtype who also have tuberculosis (TB) or Kaposi's sarcoma (KS), according to a study published in the Feb.1 issue of The Journal of Infectious Diseases, now available online. The South African subtype, known as subtype C, is rapidly spreading in developing countries, where TB and KS are major factors in AIDS morbidity and mortality. Since the triple-drug regimens have markedly reduced the morbidity and mortality associated with the subtype that predominates in developed countries (subtype B), the implication is that they may be similarly effective against the C subtype in developing countries as well.

The authors, Edana Cassol and coworkers in Durban, South Africa and the United States, studied 49 patients with previously untreated HIV-1 infection, 21 of whom had pulmonary TB and 28 of whom had KS. Patients in the TB group first received standard TB treatment, then an antiretroviral combination that has been successfully used to treat HIV-1 subtype B infections in patients with active TB--didanosine, lamivudine, and efavirenz, all purchased from Western manufacturers. KS patients received a combination of generic stavudine, lamivudine, and nevirapine, all manufactured in India; some also received cancer chemotherapy. Responses to antiretroviral therapy were measured in part by plasma HIV RNA levels and the number of peripheral blood CD4 cells, which help to orchestrate immune responses.

After three months, 94 percent of the TB group and 80 percent of the Kaposi group had undetectable HIV RNA levels--rates equivalent to or better than those in studies involving Western patients infected with the B subtype. The decrease occurred rapidly during the first 7 days of treatment, then gradually until virus was undetectable--a pattern reported in Western B subtype-
'"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
28-Dec-2004


Page: 1 2

Related medicine news :

1. Study shows patch therapy may be as effective as oral medications
2. Novel therapy tested in mice could chase away cat allergies
3. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack
4. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
5. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
6. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
7. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
8. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
9. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
10. Cognitive behavioral therapy and medication is effective in the treatment of panic disorder
11. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: